This biomarker is also known as:
- protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1),
- EC 18.104.22.168,
- MAPK/ERK kinase 1,
- ERK activator kinase 1,
- MEK 1,
- dual specificity mitogen-activated protein kinase kinase 1,
- MAPKK 1,
- mitogen-activated protein kinase kinase 1,
- MAP kinase kinase 1,
View in BioMuta
MAP2K1, or mitogen-activated protein kinase kinase 1, is a dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals. MAP2K1 is located upstream of MAP kinases and stimulates the enzymatic activity of MAP kinases upon wide variety of extra- and intracellular signals. MAP2K1 is thought to be involved in binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors, as well as cellular processes such as proliferation, differentiation, transcription regulation and development.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
No additional breast data available.
MAP2K1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.